# Avalon Globocare Corp (ALBT)

**Exchange:** NASDAQ  
**Sector:** Real Estate  
**Market cap:** $325,941.663  
**Price:** $0.35 (-2.52%)

> Avalon GloboCare Corp. is a commercial-stage company focused on developing and delivering precision diagnostic consumer products, advancing cellular therapy intellectual property, and owning commercial real estate properties in the United States. It markets the KetoAir™ breathalyzer, a handheld nanosensor device that measures breath acetone levels to monitor ketosis and fat metabolism, integrated into wellness programs for first responders and ketogenic health management. The company distributes KetoAir™ through wholesale agreements, affiliate programs, and online channels in the United States and United Kingdom, while co-developing additional applications like a cannabis breathalyzer for point-of-care detection. Avalon GloboCare Corp. advances proprietary CAR-T and CAR-NK cell technologies, including bispecific designs and cytokine induction methods protected by patents in multiple jurisdictions. Through subsidiaries like Avalon Quantum AI, LLC and Q&A Distribution, LLC, it operates generative AI software for nutrition and publishing, alongside real estate operations. Founded in 2015 and headquartered in Freehold, New Jersey, Avalon GloboCare Corp. plays a role in the intersection of diagnostics, biotech IP, AI-enabled health tools, and property management within healthcare and real estate markets.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2024 | $1M | — | -$5M | -$8M | — |
| 2023 | $1M | — | -$16M | -$17M | — |
| 2022 | $1M | $272,728 | -$9M | -$12M | — |
| 2021 | $1M | $414,518 | -$9M | -$9M | — |
| 2020 | $1M | $390,203 | -$12M | -$13M | — |
| 2019 | $2M | $339,913 | -$19M | -$18M | — |
| 2018 | $2M | $388,014 | -$8M | -$8M | — |
| 2017 | $1M | $49,789 | -$4M | -$4M | — |
| 2016 | $616,446 | -$543,380 | $76,933 | $55,581 | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2024 | $21M | $14M | $7M | $3M | — |
| 2023 | $21M | $13M | $7M | $285,400 | — |
| 2022 | $20M | $9M | $11M | $2M | — |
| 2021 | $10M | $7M | $3M | $807,538 | $3M |
| 2020 | $10M | $6M | $4M | $726,577 | — |
| 2019 | $10M | $6M | $4M | $764,891 | — |
| 2018 | $13M | $2M | $11M | $2M | — |
| 2017 | $13M | $5M | $8M | $3M | — |
| 2016 | $4M | — | $4M | $3M | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2024 | -$5M | — | — |
| 2023 | -$7M | $22,159 | -$7M |
| 2022 | -$7M | $1,749 | -$7M |
| 2021 | -$5M | $17,502 | -$5M |
| 2020 | -$8M | — | — |
| 2019 | -$7M | — | — |
| 2018 | -$4M | — | — |
| 2017 | -$1M | $148,010 | -$1M |
| 2016 | $13,984 | $334 | $13,650 |
| 2015 | -$30,106 | — | — |

Source: [CompaniesByCap](https://companiesbycap.com/company/ALBT)